Blog

Company News

Industry Trends

Laws Regulations

All Categories >

10

2026-02

Announcement on the Addition and Activation of the Company Name “Wuxi Hycells Biotechnology Co., Ltd.”

It will be comprehensively upgraded into the operations, production, and business hub of the Hycells Bio-system, centrally handling external procurement of products, technical services, project collaborations, and various other business partnerships. Following the restructuring, the two companies will collaborate on undertaking and jointly executing relevant business activities while assuming corresponding responsibilities.

2026-02-10

He Yousheng

09

2026-02

Good News | Hycells Bio Completes Tens of Millions in Pre-A Round Funding

Recently, Wuxi Hycells Biotechnology Co., Ltd.—a biotech company specializing in primary cell technologies and innovative solutions—announced the completion of a Pre-A round of financing totaling several tens of millions of RMB. This round was co-led by Guolian Jintou Zhiyuan, the core market-oriented fund investment platform under Wuxi Guolian Group, together with the Wuxi Xidong Industrial Investment Center. The funds will be primarily used to drive the iterative upgrade of the company’s GMP-compliant products, accelerate its global business expansion, and further strengthen its integrated product-and-service solutions centered on primary cells.

2026-02-09

He Yousheng

05

2026-02

Uniting Hearts and Pooling Strength, Galloping into a New Journey | The 2026 Annual Celebration of Hycells Concludes Successfully

Recently, the 2026 Hycells Annual Gala, themed “Uniting Hearts and Pooling Strengths for a New Leap Forward,” was grandly held at Club Med Joyview Anji Resort.

2026-02-05

He Yousheng

02

2026-02

HiMag: Defining High Standards for Primary Cell Sorting

The high heterogeneity of immune cells underpins the complex and precise regulation of the host immune response. Efficient sorting and purification of specific immune cell subsets in mouse models are essential prerequisites for elucidating immune mechanisms, establishing disease models, and developing therapeutic strategies.

2026-02-02

He Yousheng

05

2026-01

Hycells Recruitment | Continuous Exploration and Innovation

Hycells Bio is a biotechnology company specializing in primary cell technologies and innovative solutions. Headquartered in Wuxi, the company operates dual hubs in Wuxi and Shanghai: the Wuxi center focuses on product R&D, manufacturing, and commercialization, while the Shanghai center concentrates on primary cell preparation and technical services. The company is committed to providing domestically developed, proprietary tools and technologies for biopharmaceutical R&D and manufacturing. Leveraging its independent technology platform, it has launched a comprehensive portfolio of products, including primary immune cells, stem cells, primary animal cells, flow cytometry antibodies for CAR-positive rate detection, immune cell expansion culture media, stem cell expansion and differentiation media, cryopreservation solutions, and cell culture additives. In addition, drawing on its rich resources and technological strengths in primary cells, the company has expanded into in vitro efficacy evaluation, drug immunogenicity assessment, and in vitro blood toxicity testing services. Several of its products and services have already broken the long-standing monopoly held by foreign suppliers, achieving domestic substitution and even surpassing their performance.

2026-01-05

He Yousheng

09

2025-12

Integrated Cultivation and Empowerment for Healthy Aging | Professor Zhang Xianzheng of Wuhan University Publishes in Advanced Materials, Revealing a Novel Strategy for Reprogramming Aging (IF: 26.8)

Recently, Professor Xianzheng Zhang’s team from the School of Chemistry and Molecular Sciences at Wuhan University published a research paper titled “Senescence Reprogramming Unleashes Tumor Immune Surveillance via Coordinated Gene Modulation” in the top materials science journal Advanced Materials. This study proposes an innovative cancer therapy strategy that achieves tumor-specific senescence reprogramming by jointly regulating two key targets—P16INK4a and PD-L1—thereby activating the immune system to combat tumors.

2025-12-09

He Yousheng
< 1234...20 >